/

DBVT

DBV Technologies S.A.Open

9.08−0.48 −4.97%USD

NasdaqCM · as of Oct 13, 15:49 ET · 15m delay

Open

9.47

Prev close

9.55

Day range

8.979.48

52-week range

8.9726.19

Volume

272.86K0.79×

Mkt cap

570.35M

P/E ttm

—

Fwd P/E

-18.67

EPS ttm

-3.50

Div yield

0.00%

Earnings

Oct 28, 2026

From 52w high

−65.34%

Price Chart

Yahoo Finance · delayed

DBVTOct 13, 2026O 9.47H 9.48L 8.97C 9.07−0.48 (−4.97%)Vol 272.86K

SMA 5012.71
SMA 20017.50

1Y change −39.50% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DBVT DBV Technologies S.A. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.07%
1 month: −23.42%
3 months: −43.00%
6 months: −58.06%
Year to date: −52.66%
1 year: −44.75%

Valuation & ownership

Market cap: 570.35M
Enterprise value: 398.00M
P/E (ttm): —
Forward P/E: -18.67
PEG ratio: —
Price / book: 3.35
Price / sales (ttm): 113.25
EV / EBITDA: -2.28
EPS (ttm): -3.50
EPS (forward): -0.4862
Beta (5y monthly): -0.24
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 62.85M
Float: 31.89M
Short % of float: 1.79%
Short ratio (days): 3.29
Held by insiders: 0.00%
Held by institutions: 41.66%
Avg volume (3m): 344.80K
50-day average: 12.80
200-day average: 17.55
52-week change: −44.75%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 24.6
vs 50-day SMA: −28.57%
vs 200-day SMA: −48.13%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.46%
Realised vol (20d, ann.): 51.2%
From 52-week high: −65.34%
From 52-week low: +1.23%

ANR

Analyst Consensus

7 analysts

Consensus

Buy

1.71 on a 1 (strong buy) – 5 (sell) scale

Mean target

38.60

+325.30% implied

Low 5.69Median 44.48High 54.37

Recommendation trend

Now6 / 0 / 1
1m ago / 0 /

DES

About DBV Technologies S.A.

Yahoo Finance profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Sector: Healthcare
Industry: Biotechnology
Employees: 170
Headquarters: Châtillon, France
Website: dbv-technologies.com
Officers: Mr. Daniel Tassé CEO & Director
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. Chief Financial Officer
Dr. Pharis Mohideen M.D. Chief Medical Officer

SEAS

Seasonality · DBVT

2014–2026 · monthly returns

Strongest month Nov +34.98%Weakest month Oct −11.41%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	12.7	-2.9	-0.5	0.5	-9.0	-14.1	-17.7	2.4	-14.9	-22.8			−52.7%
2025	36.7	5.3	53.3	32.1	-7.3	9.7	-7.1	13.4	3.6	46.4	-10.6	46.4	+520.4%
2024	-3.8	-10.6	-8.7	-11.6	-15.4	-28.5	21.0	-7.1	-22.2	11.1	401.3	-20.8	+62.1%
2023	-13.7	9.8	16.6	-11.8	30.9	-2.6	-22.1	6.8	-13.9	-25.7	-26.7	28.8	−37.7%
2022	-4.4	-12.4	18.7	-18.9	17.1	68.9	0.0	-21.2	-11.9	-14.1	-11.2	13.3	−4.4%
2021	96.2	4.1	-0.4	22.5	-10.4	-6.7	-4.8	13.8	-17.2	-38.2	-1.0	-46.7	−38.9%
2020	-9.1	0.6	-60.0	58.7	-22.0	-9.5	-6.4	-47.4	-19.9	-17.3	71.3	6.9	−75.5%
2019	5.1	20.6	-5.3	26.5	-7.5	-8.9	15.2	-3.9	-5.5	-16.9	9.1	37.2	+66.7%
2018	-5.9	-7.8	8.0	-4.9	2.5	-14.3	-6.5	23.3	1.0	-17.9	-18.1	-57.5	−73.9%
2017	-1.7	5.5	-3.3	0.3	-6.0	7.6	24.7	-0.9	-3.9	-44.8	-2.5	7.7	−30.0%
2016	-28.4	-3.2	29.4	4.4	-1.3	-2.7	6.1	-0.1	5.1	-5.5	6.4	-3.8	−3.2%
2015	-10.4	-10.8	7.8	7.3	-6.1	26.5	46.4	-10.5	-8.8	-2.6	0.6	4.1	+33.9%
2014											1.2	6.1	+7.4%

INSD

Insider Activity · DBVT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 28, 2026	Mohideen PharisOfficer	Sale at price 22.96 per share.	534	$12.26K
Jul 28, 2025	Mohideen PharisOfficer	Sale at price 9.80 per share.	464	$4.55K
Nov 24, 2024	Mohideen PharisOfficer	Sale at price 0.53 - 0.57 per share.	907	$503

13F

Investors Holding DBVT

latest 13F filings of 29 followed managers

Investors holding DBVT
Investor	Value	Of portfolio	Shares	Change	Quarter
Duquesne Family Office · Stanley Druckenmiller	$6.3M	0.12%	383.36K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

DBVT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DBVT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About DBV Technologies S.A.

Seasonality · DBVT

Insider Activity · DBVT

Congress Trades · DBVT

Investors Holding DBVT

Investors Holding DBVT

Congress Trades · DBVT

Seasonality · DBVT

Insider Activity · DBVT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About DBV Technologies S.A.

Financial Snapshot

Earnings & Dividends

News